Abstract
Introduction: Coronavirus disease 2019 (COVID-19) is characterised by a pro-coagulant state that can lead to thromboembolic events. A high prevalence of Lupus Anti-coagulant has been shown in several studies, that may atleast partially explain the procoagulant prole of COVID-19. Few people infected by Coronavirus have become seriously ill while others showed little or no signs or symptoms related to COVID-19. This study was undertaken to analyze Haematological, Immunohaematological parameters and clinical Chemistry prole among LA positive and LA negative COVID -19 cases. Objectives: 1. To assess clinical, hematological and coagulation prole in COVID-19 lupus anticoagulant positive cases and lupus anticoagulant negative cases .. 2. To correlate ndings amongst lupus anticoagulant positive and negative cases. 3. To assess inammatory status amongst Covid-19 lupus anticoagulant positive and negative cases with markers like Crp-q, LDH, D-Dimer and Ferritin. Materials and Methods: The study was conducted as a prospective observational study with search data forms from the case records of patients hospitalized as ICU/ non- ICU COVID-19 cases in MGM Hospital and Medical College, Aurangabad during the pandemic for a total duration of 2 years from December 2020 to December 2022. A total of 90 patients with conrmed diagnosis of COVID-19 by RTPCR/RAT were studied. To assess Lupus Anti-Coagulant positivity- Dilute Russel Viper venom time (DRVVT) technique is used for established COVID-19 cases Conclusion: In conclusion, the current study conrmed no statistical correlation for parameters such as age, gender, comorbidities (hypertension, diabetes mellitus, COPD, IHD) in LA positive and LA negative cases. There was no statistical correlation found for ANA, RA factor, Inammatory markers and Coagulation prole among LA positive and LA negative cases. Neutrophil : Lymphocyte ratio and Lymphocyte : CRP ratio did not statistically differ in LA positive and LA negative cases. Complications (stroke, IC bleed, DVT, PTE) were observed in 16.27% LA negative patients while none of the above complications were seen in LA positive patients. Further large scale studies are required to comment on differences in Haematological, Immunohaematological and Clinical Chemistry prole between LA positive and LA negative cases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
